Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Edwards Lifesciences Corp

Healthcare US EW

86.02USD
-1.64(1.87%)

Last update at 2026-06-03T20:10:00Z

Day Range

85.8187.90
LowHigh

52 Week Range

72.3087.89
LowHigh

Fundamentals

  • Previous Close 87.66
  • Market Cap46295.57M
  • Volume4905490
  • P/E Ratio45.03
  • Dividend Yield-%
  • EBITDA1794.50M
  • Revenue TTM6067.60M
  • Revenue Per Share TTM10.38
  • Gross Profit TTM 4733.40M
  • Diluted EPS TTM1.77

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1272.90M 1548.10M 1598.10M 1767.40M 1702.00M
Minority interest 4.10M 4.90M 3.00M - -
Net income 1073.50M 4174.60M 1402.40M 1521.90M 1503.10M
Selling general administrative 2085.20M 1789.20M 1755.60M 1567.60M 1493.70M
Selling and marketing expenses - - 1.20M - -
Gross profit 4740.70M 4322.00M 4625.00M 4302.00M 3983.60M
Reconciled depreciation 156.60M 155.20M 143.60M 139.60M 134.80M
Ebit 1272.90M 1567.90M 1534.10M 1748.50M 1348.50M
Ebitda 1429.50M 1723.10M 1534.10M 1829.90M 1483.30M
Depreciation and amortization 156.60M 155.20M 144.90M 81.40M 134.80M
Non operating income net other - - - 38.10M 30.10M
Operating income 1636.20M 1378.70M 1534.10M 1748.50M 1348.50M
Other operating expenses 4431.40M 4060.80M 4276.20M 3593.20M 3645.70M
Interest expense 20.40M 19.80M 17.60M 19.20M 18.40M
Tax provision 216.90M 152.10M 207.60M 245.50M 198.90M
Interest income 148.40M 120.30M 67.20M 16.30M 1.00M
Net interest income 148.40M 100.50M 40.70M 16.30M -1.00000M
Extraordinary items 13.40M 2773.70M 179.40M - -
Non recurring - - - 76.50M 20.60M
Other items - - - - -
Income tax expense 216.90M 152.10M 198.70M 245.50M 198.90M
Total revenue 6067.60M 5439.50M 6004.80M 5382.40M 5232.50M
Total operating expenses 3104.50M 2943.30M 2896.40M 2512.80M 2396.80M
Cost of revenue 1326.90M 1117.50M 1379.80M 1080.40M 1248.90M
Total other income expense net -363.30000M 169.40M 64.00M 18.90M 353.50M
Discontinued operations - - - - -
Net income from continuing ops 1056.00M 1396.00M 1428.10M 1521.90M 1503.10M
Net income applicable to common shares 1073.50M 4174.60M 1402.40M 1521.90M 1503.10M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 13697.20M 13055.30M 9363.20M 8292.50M 8502.60M
Intangible assets 1128.20M 1176.60M 399.40M 285.20M 323.60M
Earning assets - - - - -
Other current assets 473.80M 495.40M 671.30M 195.90M 237.10M
Total liab 3359.60M 2992.40M 2643.80M 2485.80M 2666.70M
Total stockholder equity 10337.60M 9998.40M 6650.00M 5806.70M 5835.90M
Deferred long term liab - - - - -
Other current liab 1534.50M 856.00M 879.40M 311.00M 3.90M
Common stock 658.70M 654.80M 650.50M 646.30M 642.00M
Capital stock 658.70M 654.80M 650.50M 646.30M 642.00M
Retained earnings 14240.50M 13167.00M 8992.40M 7590.00M 6068.10M
Other liab - - - 797.60M 969.60M
Good will 1768.60M 1776.70M 1145.10M 1164.30M 1167.90M
Other assets 1379.80M 1724.50M 1218.30M 783.10M 357.50M
Cash 2938.50M 3045.20M 1132.30M 769.00M 862.80M
Cash and equivalents 2938.00M 3045.20M 1144.00M 769.00M 862.80M
Total current liabilities 1813.70M 1505.20M 1195.40M 1022.40M 1032.30M
Current deferred revenue 27.20M 53.70M 953.90M 484.00M 798.40M
Net debt -2233.10000M -2345.20000M -447.20000M -77.70000M -172.50000M
Short term debt 24.50M 23.40M 22.90M 25.50M 25.50M
Short long term debt - - - - -
Short long term debt total 705.40M 700.00M 685.10M 691.30M 690.30M
Other stockholder equity -4323.30000M -3578.90000M -2750.10000M -2174.70000M -716.50000M
Property plant equipment 1914.60M 1784.20M 1843.40M 1725.10M 1638.70M
Total current assets 6738.90M 6285.40M 4035.70M 3095.80M 3180.70M
Long term investments 278.60M 307.90M 583.90M 1239.00M 1834.20M
Net tangible assets - - - 4357.20M 4344.40M
Short term investments 1288.30M 930.70M 500.50M 446.30M 604.00M
Net receivables 912.10M 727.40M 828.10M 699.10M 664.90M
Long term debt 598.30M 597.70M 597.00M 596.30M 595.70M
Inventory 1126.20M 1086.70M 903.50M 875.50M 726.70M
Accounts payable 227.50M 197.40M 186.60M 201.90M 204.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -238.30000M -244.50000M -242.80000M -254.90000M -157.70000M
Additional paid in capital - - - - -
Common stock total equity - - - 646.30M 642.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 7590.00M 6068.10M
Treasury stock - - - - -2416.90000M
Accumulated amortization - - - - -
Non currrent assets other 234.90M 732.40M 774.30M 299.10M 110.80M
Deferred long term asset charges - - - - -
Non current assets total 6958.30M 6769.90M 5327.50M 5196.70M 5321.90M
Capital lease obligations 107.10M 102.30M 97.90M 95.00M 94.60M
Long term debt total 598.30M 597.70M 597.00M 596.30M 595.70M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -282.10000M 2312.90M 254.40M 252.30M -1335.20000M
Change to liabilities - - - -27.00000M 257.20M
Total cashflows from investing activities -712.90000M 2312.90M 173.80M 252.30M -1722.50000M
Net borrowings - - -0.30000M -0.20000M -1.80000M
Total cash from financing activities -956.80000M -983.00000M -711.00000M -1584.50000M -356.30000M
Change to operating activities - - - -96.90000M -39.80000M
Net income 1069.40M 4169.70M 1402.40M 1521.90M 1503.10M
Change in cash -119.30000M 1910.80M 375.40M -94.80000M -332.80000M
Begin period cash flow 3058.80M 1148.00M 772.60M 867.40M 1200.20M
End period cash flow 2939.50M 3058.80M 1148.00M 772.60M 867.40M
Total cash from operating activities 1595.20M 542.30M 895.80M 1218.20M 1732.10M
Issuance of capital stock - - - - -
Depreciation 156.60M 155.20M 144.90M 139.60M 134.80M
Other cashflows from investing activities -195.70000M 3745.30M -75.00000M 517.10M -61.50000M
Dividends paid - - 169.90M - -
Change to inventory 50.70M -256.10000M -289.00000M -213.40000M 19.00M
Change to account receivables -23.00000M 121.20M -141.20000M -84.10000M -112.40000M
Sale purchase of stock -893.40000M -1159.40000M -879.60000M -1727.10000M -512.80000M
Other cashflows from financing activities -237.50000M 176.40M 168.90M 142.80M 163.50M
Change to netincome - - - -49.10000M -79.60000M
Capital expenditures 260.20M 252.40M 266.30M 264.80M 329.80M
Change receivables - - - -84.10000M -91.10000M
Cash flows other operating - - - 1452.20M 1491.80M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -114.00000M -346.70000M
Change in working capital 154.60M -259.30000M -526.30000M -421.40000M 145.30M
Stock based compensation 158.10M 162.30M 139.40M 126.80M 109.30M
Other non cash items 174.10M -3362.20000M 7.50M 105.80M -119.00000M
Free cash flow 1335.00M 289.90M 629.50M 953.40M 1402.30M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EW
Edwards Lifesciences Corp		 -1.64 1.87% 86.02 45.03 27.40 7.63 4.54 7.16 29.96
ABT
Abbott Laboratories		 0.02 0.02% 86.99 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 1.70 0.58% 295.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 4.20 5.69% 77.95 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.01 0.02% 47.69 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corp

One Edwards Way, Irvine, CA, United States, 92614

Key Executives

Name Title Year Born
Mr. Michael A. Mussallem Chairman & CEO 1953
Mr. Scott B. Ullem Corp. VP & CFO 1967
Mr. Donald E. Bobo Jr. Corp. VP of Strategy & Corp. Devel. 1962
Mr. Larry L. Wood Corp. VP of Transcatheter Aortic Valve Replacement 1966
Mr. Jean-Luc Lemercier Corp. VP of Europe, Middle East, Africa, Canada & Latin America 1957
Dr. Todd J. Brinton Corp. VP of Advanced Technology & Chief Scientific Officer NA
Mark Wilterding VP of Investor Relations NA
Mr. Arnold A. Pinkston Corp. VP & Gen. Counsel 1959
Mr. Dirksen J. Lehman Corp. VP of Public Affairs NA
Ms. Christine Z. McCauley Corp. VP of HR 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions